The Miami Entrepreneur

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Gilead strikes deal to acquire CymaBay for $4.3 billion
Next post Oil prices pull back after surging 6% last week